抗HIV治療ガイドライン（2025年3月発行）

XVI医療従事者におけるHIVの曝露対策

文献

  1. Bell DM: Occupational risk of human immunodeficiency virus infection in healthcare workers: an overview. Am J Med. 102 (Suppl. 5B): 9-15, 1997.
  2. Ippolito G, Puro V, De Carli G. The risk of occupational human immunodeficiency virus infection in health care workers. Arch Intern Med. 153: 1451-8, 1993.
  3. Mofenson LM, Lambert JS, Stiehm ER, et al. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team. N Engl J Med. 341(6):385-93.1999.
  4. Recommendations for the Use of Antiretroviral Drugs during Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States (Last updated Dec. 19, 2024). https://clinicalinfo.hiv.gov/en/guidelines/perinatal/whats-new
  5. Rodriguez MG, Syros A, Rodriguez AE, Serota DP. The Perils of Overly Sensitive Viral Load Testing for Persons With Human Immunodeficiency Virus. Open Forum Infect Dis. 2023 Oct 3;10(10):ofad494.
  6. Broyles LN, Luo R, Boeras D, Vojnov L. The risk of sexual transmission of HIV in individuals with low-level HIV viraemia: a systematic review. Lancet. 2023 Aug 5;402(10400):464-471.
  7. Kuhar DT, Henderson DK, Struble KA, et al. Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis. Infect Control Hosp Epidemiol. 34(9):875-92. 2013.
  8. Expert Advisory Group on AIDS. Providing expert scientific advice on HIV. Updated recommendation for HIV post-exposure prophylaxis (PEP) following occupational exposure to a source with undetectable HIV viral load.
    https://www.gov.uk/government/publications/eaga-guidance-on-hiv-post-exposure-prophylaxis
  9. Young TN, Arens FJ, Kennedy GE, et al. Antiretroviral post-exposure prophylaxis (PEP) for occupational HIV exposure. Cochrane Database Syst Rev. (1):CD002835. 2007.
  10. 平成5年7月13日付　厚生省保健医療局エイズ結核感染症課長（健医感発 第78号） https://api-net.jfap.or.jp/library/data/law/doc_02_23.htm
  11. 労災保険におけるHIV感染症の取扱いについて（通知）、厚生労働省労働基準局長通知（基発0909第1号）、平成22年9月9日 https://www.mhlw.go.jp/web/t_doc?dataId=00tb6414&dataType=1&pageNo=1
  12. Mayer KH, Molina JM, Thompson MA, Anderson PL, Mounzer KC, De Wet JJ, DeJesus E, Jessen H, Grant RM, Ruane PJ, Wong P, Ebrahimi R, Zhong L, Mathias A, Callebaut C, Collins SE, Das M, McCallister S, Brainard DM, Brinson C, Clarke A, Coll P, Post FA, Hare CB. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet. 2020 Jul 25;396(10246):239-254.
  13. Lockman S, Brummel SS, Ziemba L, et al. Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet 397:1276-1292, 2021.
  14. European AIDS Clinical Society (EACS) Guidelines. Version 12.1-November 2024. https://eacs.sanfordguide.com
  15. Zash R, Makhema J, Shapiro RL. Neural-tube defects with dolutegravir treatment from the time of conception. N Engl J Med.379(10):979-81. 2018.
  16. Zash R, Holmes L, Diseko M, et al. Neural-Tube Defects and Antiretroviral Treatment Regimens in Botswana. N Engl J Med. 2019 Aug 29;381:827-840.
  17. Zash R, Holmes L, Diseko M, et al. Update on neural tube defects with antiretroviral exposure in the Tsepamo study, Botswana. 23rd International AIDS Conference 2020. #OAXLB0102.
  18. Cardo DM, Culver DH, Ciesielski CA, et al.: A case-control study of HIV seroconversion in healthcare workers after percutaneous exposure. N. Engl. J. Med. 337: 1485-90, 1997.
  19. CDC, HIV Occupational Transmission : https://www.cdc.gov/hiv/causes/occupational-transmission.html
  20. Asanati K, Majeed A, Shemtob L, et al. : Healthcare workers potentially exposed to HIV: an update. J R Soc Med. 115 :286-288, 2022.
  21. Notes from the Field: Occupationally Acquired HIV Infection Among Health Care Workers-United States, 1985-2013. MMWR January 9, 2015.
  22. New York State Department of Health AIDS Institute. Clinical guidelines program. Post-Exposure Prophylaxis (PEP) to Prevent HIV infection. (Last reviewed and updated (Oct 03, 2024) https://www.hivguidelines.org/pep-for-hiv-prevention/pep/#tab_2

PAGE TOP